MDA vs no MDA: Parasitaemia prevalence
MDA may leads to lower parasitaemia prevalence compared with no MDA (low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
MDA vs no MDA Parasitaemia prevalence · People of all ages living in an area with very low to low endemicity of P vivax malaria (< 10% prevalence) MDA may leads to lower parasitaemia prevalence compared with no MDA (low certainty). Mass drug administration for malaria (2021) · Cochrane Headline outcomes only | RR 0.18 [0.08, 0.4] | 1 study · 1232 participants | Low |
MDA vs no MDA Parasitaemia prevalence · People of all ages living in an area with very low to low endemicity of P vivax malaria (< 10% prevalence) MDA may leads to lower parasitaemia prevalence compared with no MDA (low certainty). Mass drug administration for malaria (2021) · Cochrane Headline outcomes only | RR 0.15 [0.1, 0.24] | 5 studies · 6896 participants | Low |
MDA vs no MDA Parasitaemia prevalence · People of all ages living in an area with very low to low endemicity of P vivax malaria (< 10% prevalence) It is very uncertain whether MDA changes parasitaemia prevalence compared with no MDA (very low certainty). Mass drug administration for malaria (2021) · Cochrane Headline outcomes only | RR 0.81 [0.44, 1.48] | 1 study · 1537 participants | Very low |
MDA vs no MDA Parasitaemia prevalence · People of all ages living in an area with very low to low endemicity of P vivax malaria (< 10% prevalence) It is very uncertain whether MDA changes parasitaemia prevalence compared with no MDA (very low certainty). Mass drug administration for malaria (2021) · Cochrane Headline outcomes only | RR 0.84 [0.38, 1.83] | 1 study · 1393 participants | Very low |
MDA vs no MDA Parasitaemia prevalence · People of all ages living in an area with very low to low endemicity of P vivax malaria (< 10% prevalence) It is very uncertain whether MDA changes parasitaemia prevalence compared with no MDA (very low certainty). Mass drug administration for malaria (2021) · Cochrane Headline outcomes only | RR 0.89 [0.41, 1.94] | 1 study · 1521 participants | Very low |
MDA vs no MDA Parasitaemia prevalence · People of all ages living in an area with very low to low endemicity of P vivax malaria (< 10% prevalence) It is very uncertain whether MDA changes parasitaemia prevalence compared with no MDA (very low certainty). Mass drug administration for malaria (2021) · Cochrane Headline outcomes only | RR 1.2 [0.44, 3.29] | 1 study · 1679 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Mass drug administration for malaria 2021 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.